Arcutis Biotherapeutics, Inc. (ARQT) Balance Sheet
As of 2026-06-30 (10-Q), Arcutis Biotherapeutics, Inc. (ARQT) reported total assets of $488.5M, total liabilities of $268.0M and shareholders' equity of $220.6M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $34.1M. Long-term debt: $102.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ARQTArcutis Biotherapeutics, Inc.Follow ARQT — free
—
Price chart with a free account
- Market cap
- 3.9B
- P/E TTM
- 148.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 65.1 | 96.4 | 53.6 | 88.4 | 71.3 | 42.9 | 34.1 | |
| Short-term investments | 219.4 | 290.6 | 355.9 | 183.5 | 156.6 | 178.1 | 204.4 | |
| Receivables | — | 0.0 | 8.5 | 25.8 | 73.1 | 146.2 | 155.2 | |
| Inventory | — | 0.0 | 7.5 | 13.1 | 14.5 | 22.6 | 38.9 | |
| Current assets | 292.8 | 402.8 | 437.4 | 330.4 | 335.8 | 411.2 | 467.7 | |
| Total assets | 298.3 | 408.2 | 449.3 | 341.4 | 348.9 | 433.0 | 488.5 | |
| Current liabilities | 22.6 | 33.3 | 37.8 | 46.7 | 81.0 | 129.8 | 160.3 | |
| Long-term debt | 0.0 | 72.4 | 197.8 | 201.8 | 107.2 | 108.0 | 102.0 | |
| Short-term debt | — | — | — | 0.0 | 0.0 | 1.0 | 7.0 | |
| Total liabilities | 27.6 | 110.5 | 239.7 | 252.7 | 191.3 | 243.5 | 268.0 | |
| Shareholders' equity | 270.6 | 297.7 | 209.6 | 88.7 | 157.5 | 189.5 | 220.6 |
USD millions · SEC XBRL
Arcutis Biotherapeutics, Inc. — questions
- How much cash does Arcutis Biotherapeutics, Inc. have?
- $34.1M in cash and cash equivalents as of 2026-06-30.
- How much debt does Arcutis Biotherapeutics, Inc. have?
- $102.0M of long-term debt and $7.0M due within a year as of 2026-06-30.
- What are Arcutis Biotherapeutics, Inc.'s total assets?
- $488.5M as of 2026-06-30.
- What is Arcutis Biotherapeutics, Inc.'s shareholders' equity?
- $220.6M as of 2026-06-30.
Every figure on this page comes from Arcutis Biotherapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.